KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other financing activities (2020 - 2025)

Esperion Therapeutics filings provide 6 years of Other financing activities readings, the most recent being $244000.0 for Q4 2025.

  • On a quarterly basis, Other financing activities fell 97.47% to $244000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $8.5 million, a 13.05% decrease, with the full-year FY2025 number at $244000.0, down 97.47% from a year prior.
  • Other financing activities hit $244000.0 in Q4 2025 for Esperion Therapeutics, down from $400000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $9.6 million in Q4 2024 to a low of -$438000.0 in Q4 2022.
  • Median Other financing activities over the past 5 years was $400000.0 (2023), compared with a mean of $1.5 million.
  • Biggest five-year swings in Other financing activities: surged 45738.1% in 2024 and later plummeted 97.47% in 2025.
  • Esperion Therapeutics' Other financing activities stood at $500000.0 in 2021, then tumbled by 187.6% to -$438000.0 in 2022, then skyrocketed by 104.79% to $21000.0 in 2023, then surged by 45738.1% to $9.6 million in 2024, then crashed by 97.47% to $244000.0 in 2025.
  • The last three reported values for Other financing activities were $244000.0 (Q4 2025), $400000.0 (Q3 2025), and $400000.0 (Q2 2025) per Business Quant data.